We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Jerini AG Reaches Agreement to Sell JPT Peptide Technologies to TheraCode
News

Jerini AG Reaches Agreement to Sell JPT Peptide Technologies to TheraCode

Jerini AG Reaches Agreement to Sell JPT Peptide Technologies to TheraCode
News

Jerini AG Reaches Agreement to Sell JPT Peptide Technologies to TheraCode

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Jerini AG Reaches Agreement to Sell JPT Peptide Technologies to TheraCode"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Jerini AG has reached an agreement to sell its wholly-owned subsidiary, JPT Peptide Technologies GmbH to TheraCode GmbH, Mainz, a wholly-owned subsidiary of BioNTech AG, Mainz.

Under the terms of the agreement, TheraCode GmbH will pay Jerini AG a purchase price of approximately € 5 million in cash. The sale of JPT Peptide Technologies GmbH to TheraCode GmbH is a further achievement in the implementation of Jerini AG's strategic decision published on October 10, 2008 to divest all non-strategic businesses and to focus on the core business Firazyr.
Advertisement